Senior Research Scientist
Dr Tim Johanssen leads a drug discovery project researching novel combinatorial treatments of glioblastoma in the High Throughput Screening Group at The University of Oxford. His work has generated a concise chemogenomic library along with drug and radiation resistant patient-derived stem cells, which have formed the basis of ongoing large-scale screens in the group.
Tim completed is PhD in neuroscience at the University of Melbourne studying the effects of beta amyloid toxicity in Alzheimer’s disease. Prior to his current position Tim has worked in industry at Eisai London Laboratories and academia at the University of Melbourne before joining the ARUK Oxford Drug Discovery Institute at the University of Oxford.
Throughout his career he has undertaken translation drug discovery research in CNS disorders. His preclinical research has employed in vitro and in vivo models of neurodegenerative diseases and glioblastoma with the aim to translate knowledge on the mechanisms underlying these diseases into the design of novel therapeutics and diagnostics.
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
Johanssen T. et al, (2023), Frontiers in Oncology, 12
Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons
Gunn AP. et al, (2016), Journal of Biological Chemistry, 291, 6134 - 6145
PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning
Johanssen T. et al, (2015), Neurobiology of Disease, 81, 176 - 185
C-terminal peptides modelling constitutive PrPCprocessing demonstrate ameliorated toxicity predisposition consequent to α-cleavage
Johanssen VA. et al, (2014), Biochemical Journal, 459, 103 - 115
Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples
Watt AD. et al, (2013), Acta Neuropathologica, 125, 549 - 564